

Special Issue

Immune Checkpoints and Autoimmunity

Message from the Guest Editor

Immune checkpoint molecules have emerged as key regulators of the immune system. They are crucial for self-tolerance but also for the activation of the immune system. To date, most studies have investigated the role of immune checkpoints in cancers, while fewer data are available in autoimmune and inflammatory diseases. Upregulation of inhibitory checkpoint molecules by cancer cells or in the tumor microenvironment can favor cancer cell escape from immune surveillance. Drugs which are able to block the inhibitory checkpoint molecules have shown efficacy in some types of cancers. On the other hand, they are sometimes coupled with the onset of immune-mediated reactions. Once the role of immune checkpoints in autoimmune and inflammatory diseases is defined, drugs and approaches able to modulate such molecules can be used for therapy. We invite authors to submit original research (basic, translational, and clinical research) and review articles about the deregulation, biological functions, and therapeutic potential of immune checkpoints in autoimmune and inflammatory diseases.

Guest Editor

Dr. Stefania Croci

Clinical Immunology, Allergy and Advanced Biotechnologies Unit,
Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/62299

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).